Hippo-YAP/TAZ signalling in the ageing brain and neurological disorders: a review
This review describes how the Hippo pathway and its effectors YAP and TAZ act in the ageing brain and in neurological disorders, and discusses experimental strategies that target this pathway. The abstract reports no new patient data. [1]
Automatic summary · not editorially reviewed
The key findings
Ageing is described as the main risk factor driving the growing burden of neurological disorders. [1]
The review summarises normal functions of Hippo-YAP/TAZ signalling in the ageing brain and its mechanistic involvement in major neurological disorders. [1]
The authors position the Hippo-YAP/TAZ pathway as a promising therapeutic target for disease-modifying interventions against ageing-associated neurological disorders. [1]
The source at a glance
- Study type / format
- Narrative review (abstract only)
- Population / context
- Not specified in the abstract; the review concerns the ageing brain and neurological disorders generally.
- Summary based on
- Study abstract
- Original publication
- October 14, 2026
Ageing as main risk factor for neurological disorders
The review starts from the observation that life expectancy is rising worldwide and that ageing is described as the main risk factor behind the growing burden of neurological disorders. Current therapies are called largely symptomatic and unable to stop disease progression. The authors say evidence is growing that these disorders share molecular mechanisms, including oxidative stress, mitochondrial dysfunction, neuroinflammation, impaired autophagy, ferroptosis and disruption of the blood-brain barrier.
Supporting source [1]
Review of Hippo-YAP/TAZ roles in the ageing brain
This is a review, not a new study. The authors summarise what is known about the normal functions of Hippo-YAP/TAZ signalling in the ageing brain and discuss how the pathway is mechanistically involved in major neurological disorders. They also describe crosstalk between Hippo signalling and pathways that regulate inflammation, oxidative stress, autophagy and mitochondrial homeostasis. The abstract does not report which studies, models or species were included.
Supporting source [1]
Therapeutic strategies proposed, but no human benefit shown
The review discusses recent therapeutic approaches that target Hippo signalling, including small-molecule modulators, drug repurposing and natural bioactive compounds, along with current challenges and future perspectives. The authors conclude that the available evidence positions the Hippo-YAP/TAZ pathway as a promising therapeutic target for disease-modifying interventions against ageing-associated neurological disorders. This is a perspective on a target, not a demonstration that any intervention prevents or treats disease in people.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. No study design, sample, model organism, follow-up or outcome data are reported in the abstract. The therapeutic outlook is the authors' perspective, not demonstrated human benefit.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Dutta BJ, Patil VS, Seksaria S, Verma S, Basak S. · europepmc.org · October 14, 2026